Company / Depreciation & Amortization
BridgeBio Pharma, Inc. Depreciation & Amortization History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$5.4M
FY2025
5-year range
$859.0K / $6.8M
FY2021-FY2025
Trend
-10.6%
vs FY2024
Sector context
#76 of 163
Health Care
What the data says
At $5M, BridgeBio Pharma, Inc.'s depreciation & amortization ranks #88 of 163 in the Health Care sector. Depreciation & Amortization has fluctuated over the past 7 years, ranging from $859,000 in FY2021 to $7M in FY2022.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of +30.1%.
Improved from $6M to $5M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -7.1%
- 5-Year CAGR
- +30.1%
- 10-Year CAGR
- -
Sector benchmark
#88 of 163 in Health CareTop 53% of 163This company $5.4M Sector average $219.4M
▼
-97.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +30.1%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 10.6% year-over-year.
- Ranks #76 out of 163 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.4M | -10.6% |
| FY2024 | $6.1M | +4.0% |
| FY2023 | $5.8M | -13.7% |
| FY2022 | $6.8M | +688.2% |
| FY2021 | $859.0K | -41.0% |
| FY2020 | $1.5M | +69.5% |
| FY2019 | $859.0K | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026